PEEKABOO EARLY GENDER DNA TEST

Clinical Study Summary

Peekaboo™: A Highly Accurate Molecular Test for Fetal Sex as Early as 6 Weeks of Gestation

A clinical study of 552 pregnant women ranging between 6 and 39 weeks of gestation (median=7 weeks) was completed to determine the utility of the Peekaboo™ Early Gender DNA Test. Maternal blood was collected by venipuncture from clinical sites in the U.S.A., and all samples were sent to DNA Diagnostics Center for processing. Cell-free DNA was extracted, and sex was determined using the proprietary qPCR-based Peekaboo™ test. Confirmation of the Peekaboo™ result was through next-generation sequencing (NGS) of the extracted DNA, customer feedback metrics, or post-natal maternal questionnaire. Of the 551 samples in which the fetal sex could be determined, 546 (>99%) of the Peekaboo™ results matched the confirmed fetal sex. The study contained a subset of fetuses at 6 weeks of gestation, a time when most other molecular tests and ultrasound are unable to identify fetal sex.

Number of Samples	552
Sensitivity (Male Detection)	314/317 (>99%)
Specificity (Female Detection)	232/234 (>99%)
Accuracy	546/551 (>99%)
Accuracy at 6 weeks	219/222 (98.6%)
Indeterminate Results	0.2%

Peekaboo Click™	
Accuracy	80/80 (100%)*
Contaminated Samples	0
Indeterminate Results	0
Overall Preferred Method	76.7%
Easier to Use	76.7%
Less Painful	68.5%

Peekaboo™ Click: An Easier Way to Draw Blood at Home with Minimal Pain

A clinical study of 80 pregnant women was performed to assess the utility of a new at-home blood collection device, Peekaboo Click™. Peekaboo Click™ enables pregnant mothers to collect capillary blood from the upper arm into a collection tube. Participants were directed to collect a sample with both the Peekaboo Click™ device, as well as with a traditional finger lancet, the current standard of care for blood self-collection. Both samples were processed by DNA Diagnostics Center to assess sample viability and test accuracy. In all 80 Peekaboo Click™ samples, the fetal sex was confirmed to be accurate using NIPT, sonogram, or finger lancet test result (100% accuracy*). In addition, participants completed a post-collection satisfaction questionnaire to compare the Peekaboo Click™ device with the finger lancet method. Participants reported that Peekaboo Click™ was easier to use, less painful, and they believed it to be less prone to contamination compared to the finger lancet. In all measures evaluated, Peekaboo Click™ had superior performance and participant satisfaction versus the finger lancet method in this study.

**There is not a statistical difference in accuracy between Peekaboo Click™ and Peekaboo venipuncture collections according to a Fisher's Exact Test.*

Peekaboo™ is a Product of DNA Diagnostics Center (DDC)®

Founded in 1995 and acquired by Eurofins Scientific in 2021, DDC® is one of the largest private DNA-testing companies, offering diagnostic and genetic tests to help answer relationship, fertility, and health and wellness questions. DDC® provides products cleared by the FDA and EMA and is accredited for Legal Relationship Testing by the Association for the Advancement of Blood & Biotherapies (AABB), the Ministry of Justice, New York State Department of Health (NYSDOH), The College of American Pathologists (CAP), and the Clinical Laboratory Improvement Amendment (CLIA). DDC® is also accredited by the globally accepted ANSI National Accreditation Board (ANAB), Standards Council of Canada (SCC), and the National Association of Testing Authorities, Australia (NATA), to meet the international quality standards of ISO 17025.

peekaboo™
Early Gender DNA Test